Q2 Earnings Forecast for IRWD Issued By Zacks Research

Key Points

• Zacks Research estimates that Ironwood Pharmaceuticals will report earnings of $0.01 per share for Q2 2027, while the current consensus for the full-year is $0.10 per share.
• Ironwood Pharmaceuticals reported $0.14 EPS for the last quarter, surpassing expectations by $0.16 and generating revenues of $85.24 million, exceeding analyst estimates.
• Wall Street Zen upgraded Ironwood Pharmaceuticals' rating from "hold" to a "strong-buy", though the average rating remains a "Hold" with a price target of $4.94.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities researchers at Zacks Research issued their Q2 2027 earnings per share (EPS) estimates for shares of Ironwood Pharmaceuticals in a research report issued to clients and investors on Monday, September 8th. Zacks Research analyst Team forecasts that the biotechnology company will post earnings of $0.01 per share for the quarter. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.16. The firm had revenue of $85.24 million during the quarter, compared to analysts' expectations of $62.02 million. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS.

Separately, Wall Street Zen raised Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. One investment analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $4.94.

Ironwood Pharmaceuticals Stock Performance

Shares of Ironwood Pharmaceuticals stock traded up $0.07 during trading on Tuesday, reaching $1.31. 816,432 shares of the company's stock were exchanged, compared to its average volume of 1,224,465. Ironwood Pharmaceuticals has a 1-year low of $0.53 and a 1-year high of $5.13. The company has a market cap of $212.78 million, a P/E ratio of -26.19 and a beta of 0.32. The firm's 50-day moving average price is $0.98 and its 200 day moving average price is $0.96.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several large investors have recently bought and sold shares of IRWD. Armistice Capital LLC grew its holdings in shares of Ironwood Pharmaceuticals by 44.7% during the first quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company's stock worth $20,139,000 after purchasing an additional 4,232,000 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Ironwood Pharmaceuticals by 186.6% during the first quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company's stock worth $9,349,000 after purchasing an additional 4,140,439 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Ironwood Pharmaceuticals by 147.6% during the second quarter. Acadian Asset Management LLC now owns 6,549,687 shares of the biotechnology company's stock worth $4,685,000 after purchasing an additional 3,904,498 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Ironwood Pharmaceuticals by 144.3% during the second quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company's stock worth $4,422,000 after purchasing an additional 3,641,762 shares during the last quarter. Finally, Marshall Wace LLP grew its holdings in shares of Ironwood Pharmaceuticals by 616.3% during the second quarter. Marshall Wace LLP now owns 3,993,557 shares of the biotechnology company's stock worth $2,875,000 after purchasing an additional 3,436,036 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.